SLC5A2 and atrial fibrillation: Metanalysis of these trials demonstrated that SGLT2 is significantly reduced AF/AFL (RR: 0.76; 95% CI 0.65–0.90; p = 0.001), all-cause mortality (RR: 0.91; 95% CI 0.83–0.99; P = 0.03) and HF outcomes (RR: 0.73; 95% CI 0.64–0.84; p < 0.00001).